V Mautner
Overview
Explore the profile of V Mautner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ostrow K, Bergner A, Blakeley J, Evans D, Ferner R, Friedman J, et al.
Am J Med Genet A
. 2016 Oct;
173(2):407-413.
PMID: 27759912
Schwannomatosis is a tumor suppressor syndrome that causes multiple tumors along peripheral nerves. Formal diagnostic criteria were first published in 2005. Variability in clinical presentation and a relative lack of...
2.
Laycock-van Spyk S, Jim H, Thomas L, Spurlock G, Fares L, Palmer-Smith S, et al.
Clin Genet
. 2011 Jun;
80(1):93-6.
PMID: 21649642
No abstract available.
3.
Demestre M, Messerli S, Celli N, Shahhossini M, Kluwe L, Mautner V, et al.
Phytother Res
. 2008 Aug;
23(2):226-30.
PMID: 18726924
Dysfunction of the NF1 gene coding a RAS GAP is the major cause of neurofibromatosis type 1 (NF1), whereas neurofibromatosis type 2 (NF2) is caused primarily by dysfunction of the...
4.
Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher K, et al.
Hum Gene Ther
. 2008 Aug;
19(9):873-86.
PMID: 18710328
Oncolytic viruses are regulated by the tumor phenotype to replicate and lyse cancer cells selectively. To identify optimal strategies for breast cancer we compared five adenoviruses with distinct regulatory mechanisms:...
5.
Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, et al.
Hum Mutat
. 2007 Oct;
29(1):74-82.
PMID: 17960768
About 10% of neurofibromatosis type 1 (NF1) patients develop malignant peripheral nerve sheath tumors (MPNSTs) and represent considerable patient morbidity and mortality. Elucidation of the genetic mechanisms by which inherited...
6.
Young J, Green N, Mautner V, Searle P, Young L, James N
Prostate Cancer Prostatic Dis
. 2007 Aug;
11(2):187-93.
PMID: 17726452
The nitroreductase (NR)/CB1954 enzyme prodrug system has given promising results in pre-clinical studies and is currently being assessed in phase I and II clinical trials in prostate cancer. Enhanced cell...
7.
Carlisle R, Briggs S, Hale A, Green N, Fisher K, Etrych T, et al.
Gene Ther
. 2006 Jul;
13(22):1579-86.
PMID: 16810196
Use of synthetic vectors to deliver genomes of conditionally replicating lytic viruses combines the strengths of viral and non-viral approaches by enabling neutralising antibody resistant deployment of cancer virotherapy. Adenovirus...
8.
Stevenson M, Boos E, Herbert C, Hale A, Green N, Lyons M, et al.
Gene Ther
. 2005 Dec;
13(4):356-68.
PMID: 16355117
Non-human adenovirus vectors have attractive immunological properties for gene therapy but are frequently restricted by inefficient transduction of human target cells. Using chicken embryo lethal orphan (CELO) virus, we employed...
9.
Mantripragada K, Thuresson A, Piotrowski A, Diaz De Stahl T, Menzel U, Grigelionis G, et al.
J Med Genet
. 2005 Jun;
43(1):28-38.
PMID: 15944227
Background: Segmental duplications flanking the neurofibromatosis type 1 (NF1) gene locus on 17q11 mediate most gene deletions in NF1 patients. However, the large size of the gene and the complexity...
10.
Green N, Herbert C, Hale S, Hale A, Mautner V, Harkins R, et al.
Gene Ther
. 2004 Jun;
11(16):1256-63.
PMID: 15215884
Systemic delivery of adenoviral vectors is a major goal in cancer gene therapy, but is currently prohibited by rapid hepatic uptake of virus following intravenous injection with levels of viable...